Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy

Annals of Nuclear Medicine

Volumn 24, Issue 6, 2010, Pages 485-492

  Fuccio, Chiara ^a   Castellucci, Paolo ^a   Schiavina, Riccardo ^a   Santi, Ivan ^a   Allegri, Vincenzo ^a   Pettinato, Vincenzina ^a   Boschi, Stefano ^a   Martorana, Giuseppe ^a   Al Nahhas, Adil ^b   Rubello, Domenico ^c   Fanti, Stefano ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c S MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

Bone scan; Choline; Positron emission tomography (PET); Prostate cancer; PSA

Indexed keywords

3,3 DIPHOSPHONO 1,2 PROPANE DICARBON ACID TECHNETIUM 99M; CHOLINE CARBON 11; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CARBON; CHOLINE; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; BONE BIOPSY; BONE METASTASIS; BONE SCINTISCANNING; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DEGENERATIVE DISEASE; FALSE NEGATIVE RESULT; FOLLOW UP; HUMAN; HUMAN TISSUE; LUNG ALVEOLUS CELL CARCINOMA; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; BONE TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; RADIOGRAPHY; SCINTISCANNING;

AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CARBON RADIOISOTOPES; CHOLINE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77955467716     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12149-010-0390-x     Document Type: Article

References (40)

1. S Fanti C Nanni V Ambrosini MD Gross D Rubello M Farsad 2007 PET in genitourinary tract cancers Q J Nucl Med Mol Imaging 51 3 260 271 17464269 1:STN:280:DC%2BD2szmtlGisQ%3D%3D
2. SJ Freedland JC Presti Jr CL Amling, et al. 2003 Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database Urology 61 736 741 10.1016/S0090-4295(02)02526-8 12670557 (Pubitemid 36384965)
3. M Han AW Partin M Zahurak, et al. 2003 Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer J Urol 169 517 523 10.1016/S0022-5347(05)63946-8 12544300 (Pubitemid 36132976)
4. DB Chism AL Hanlon EM Horwitz, et al. 2004 A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy Int J Radiat Oncol Biol Phys 59 20 380 385 15145151
5. SG Roberts ML Blute EJ Bergstralh, et al. 2001 PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer Mayo Clin Proc 76 6 576 581 10.4065/76.6.576 11393495 1:STN:280:DC%2BD3MzhvFehtg%3D%3D
6. RE Coleman 2001 Metastatic bone disease: clinical features, pathophysiology and treatment strategies Cancer Treat Rev 27 165 176 10.1053/ctrv.2000.0210 11417967 1:CAS:528:DC%2BD3MXktlCktb4%3D (Pubitemid 32452017)
7. NW Clarke J McClure NJ George 1991 Morphometric evidence for bone resorption and replacement in prostate cancer Br J Urol 68 74 80 10.1111/j.1464-410X.1991.tb15260.x 1873694 1:STN:280:DyaK3MzjvV2ktw%3D%3D
8. RE Coleman 1997 Skeletal complications of malignancy Cancer 80 1588 1594 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G 9362426 1:STN:280:DyaK1c%2Fis1Onuw%3D%3D
9. TK Choueiri R Dreicer A Paciorek, et al. 2008 A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy J Urol 179 3 906 910 10.1016/j.juro.2007.10.059 18207194
10. SR Bott 2004 Prostate cancer: management of recurrent disease after radical prostatectomy Prostatic Dis 7 211 216 10.1038/sj.pcan.4500732 1:STN:280:DC%2BD2cvjslOrsw%3D%3D (Pubitemid 41741505)
11. S Kramer J Gorich HW Gottfried, et al. 1997 Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy Br J Radiol 70 995 999 9404201 1:STN:280: DyaK1c%2FmvVSisA%3D%3D
12. ML Cher FJ Bianco JS Lam, et al. 1998 Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy J Urol 160 1387 1391 10.1016/S0022-5347(01)62545-X 9751361 1:STN:280:DyaK1cvitF2rsw%3D%3D (Pubitemid 29480523)
13. P Gomez M Manoharan SS Kim, et al. 2004 Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated? BJU Int 94 299 302 10.1111/j.1464-410X.2004.04927.x 15291855 (Pubitemid 39120167)
14. BJ Krause M Souvatzoglou M Tincel, et al. 2008 The detection rate of 11-C choline PET/TC depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer Eur J Nucl Med Mol Imaging 35 18 23 10.1007/s00259-007-0581-4 17891394 1:CAS:528:DC%2BD2sXhsVSmtLbO (Pubitemid 350234152)
15. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer Eur Urol 44 32 38 10.1016/S0302-2838(03) 00207-0 12814672 (Pubitemid 36741372)
16. M Cimitan R Bortolus S Morassut, et al. 2006 [18]F-fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients Eur J Nucl Med Mol Imaging 33 1387 1398 10.1007/s00259-006-0150-2 16865395 (Pubitemid 44885404)
17. T Hara N Kosaka H Kishi, et al. 1998 PET imaging of prostate cancer using carbon-11-choline J Nucl Med 39 990 995 9627331 1:CAS:528:DyaK1cXktV2itrg%3D
18. J Kotzerke J Prang B Neumaier, et al. 2000 Experience with carbon-11 choline positron emission tomography in prostate cancer Eur J Nucl Med 27 1415 1419 10.1007/s002590000309 11007527 1:STN:280:DC%2BD3cvltFyguw%3D%3D
19. SH Zeisel 1981 Dietary choline: biochemistry, physiology and pharmacology Annu Rev Nutr 1 95 121 10.1146/annurev.nu.01.070181.000523 6764726 1:CAS:528:DyaL3MXkvFGrsbw%3D
20. E Ackerstaff BR Pflug JB Nelson ZM Bhujwalla 2001 Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells Cancer Res 61 9 3599 3603 11325827 1:CAS:528:DC%2BD3MXjsFCgtLY%3D
21. 11C-choline uptake in prostate cancer: a PET study Eur J Nucl Med Mol Imaging 31 317 324 10.1007/s00259-003-1377-9 14628097 1:CAS:528: DC%2BD2cXhtlygtLw%3D
22. SA Muller K Holzapfel C Seidl U Treiber BJ Krause R Senekowitsch- Schmidtke 2009 Characterization of choline uptake in prostate cancer cells following bicalutamide, docetaxel treatment Eur J Nucl Med Mol Imaging 36 9 1434 1442 10.1007/s00259-009-1117-x 19352653 1:CAS:528:DC%2BD1MXps1Cktrk%3D
23. N Lawrentschuk ID Davis DM Bolton AM Scott 2007 Diagnostic and therapeutic use of radioisotopes for bony disease in prostate cancer: current practice Int J Urol 14 2 89 95 10.1111/j.1442-2042.2006.01659.x 17302562 1:CAS:528:DC%2BD2sXjvFWlurw%3D (Pubitemid 46121943)
24. JC Clark CR Dass PF Choong 2008 Current and future treatments of bone metastases Expert Opin Emerg Drugs 13 4 609 627 10.1517/14728210802584217 19046130 1:CAS:528:DC%2BD1cXhsVCnurjL
25. JA Campa III R Payne 1992 The management of intractable bone pain: a clinician's perspective Semin Nucl Med 22 3 10 10.1016/S0001-2998(05)80151-5 1589804
26. F Saad J McKiernan J Eastham 2006 Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis Urol Oncol 24 1 4 12 16414486 1:CAS:528:DC%2BD28Xls1Cgsw%3D%3D (Pubitemid 43097349)
27. 11C] choline J Labelled Compds Radiopharm. 49 195 203 10.1002/(SICI)1099-1344(200002)43: 2<195::AID-JLCR316>3.0.CO;2-P (Pubitemid 30072211)
28. F Saad N Clarke M Colombel 2006 Natural history and treatment of bone complications in prostate cancer Eur Urol 49 3 429 440 10.1016/j.eururo.2005.12. 045 16431012 1:CAS:528:DC%2BD28XkvVagu7w%3D (Pubitemid 43259549)
29. B Dasgeb MH Mulligan CK Kim 2007 The current status of bone scintigraphy in malignant disease Semin Muscoloskelet radiol 11 4 301 311 10.1055/s-2008-1060333 (Pubitemid 351415484)
30. MR Cooperberg DP Lubeck GD Grossfeld, et al. 2002 Contemporary trends in imaging test utilization for prostate cancer staging: data from the cancer of the prostate strategic urologic research endeavor J Urol 168 491 495 10.1016/S0022-5347(05)64665-4 12131295
31. JM O'Sullivan AR Norman GJ Cook, et al. 2003 Broadening the criteria for avoiding staging bone scans in prostate cancer: a retrospective study of patients at the Royal Marsden Hospital BJU Int 92 685 689 10.1046/j.1464-410X. 2003.04480.x 14616446 (Pubitemid 37475805)
32. JE Oesterling 1993 Using PSA to eliminate the staging radionuclide bone scan. Significant economic implications Urol Clin North Am 20 705 711 7505979 1:STN:280:DyaK2c%2FpvVOltw%3D%3D
33. LF Wymenga JH Boomsma K Groenier, et al. 2001 Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase BJU Int 88 226 230 10.1046/j.1464-410x.2001.02275.x 11488734 1:STN:280:DC%2BD3Mvkt1Kiug%3D%3D (Pubitemid 32863042)
34. O Akin H Hricak 2007 Imaging of prostate cancer Radiol Clin North Am 45 1 167 182 10.1016/j.rcl.2006.10.009 17157628 (Pubitemid 44854047)
35. H Schöder K Herrmann M Gönen, et al. 2005 2-[18F]fluoro-2- deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy Clin Cancer Res 11 13 4761 4769 10.1158/1078-0432.CCR-05-0249 16000572 (Pubitemid 41557196)
36. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse J Nucl Med 44 4 556 558
37. 11C]choline positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose positron emission tomography J Urol 169 1337 1340 10.1097/01.ju.0000056901.95996.43 12629355 1:CAS:528:DC%2BD3sXhvFahs7o%3D (Pubitemid 36323779)
38. P Castellucci C Fuccio C Nanni, et al. 2009 Influence of trigger PSA and PSA kinetics on 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy J Nucl Med 50 9 1394 1400 10.2967/jnumed.108.061507 19690023 1:CAS:528:DC%2BD1MXhtFOrtb3K
39. M Beheshti R Vali P Waldenberger, et al. 2009 The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT Imaging Biol 11 6 446 454 10.1007/s11307-009-0217-0
40. M Beheshti R Vali P Waldenberger, et al. 2008 Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study Eur J Nucl Med Mol Imaging 35 10 1766 1774 10.1007/s00259-008-0788-z 18465129